Arcutis Biotherapeutics vs Krystal Biotech
Arcutis Biotherapeutics and Krystal Biotech are similar in size: $376m and $389m of revenue in their latest fiscal years. Arcutis Biotherapeutics grew faster (91.3% against 33.9%). Krystal Biotech kept more of each dollar of sales as profit: a net margin of 52.6% against -4.3%. Krystal Biotech carries less debt relative to equity (0.0% against 57.5%).
| Latest fiscal year | Arcutis BiotherapeuticsARQT, 2025 | Krystal BiotechKRYS, 2025 |
|---|---|---|
| Revenue | $376m | $389m |
| Revenue growth | 91.3% | 33.9% |
| Net income | −$16.1m | $205m |
| Operating margin | -3.3% | 41.5% |
| Net margin | -4.3% | 52.6% |
| Return on equity | -9.3% | 18.9% |
| Free cash flow | −$6.3m | $189m |
| Cash | $42.9m | $496m |
| Total debt | $109m | $0 |
| Debt to equity | 57.5% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 354 | — |
| Market value | $4.02bn | $9.00bn |
| Price vs our value range | — | Within our value range |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 77 sales | 0 buys, 142 sales |